Consensus Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
5.35 ^USD	+7.00%		-0.37%	-14.40%

Apr. 01	Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	MT
Apr. 01	HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	MT

Evolution of the average Target Price on Affimed N.V.

Price target over the last 5 years

History of analyst recommendation changes

7c2522f.xszjRJZlq49m9UvDZOo6-8wBD7eoYnf_HEBo9QvMfNo.pba3IqMv5cwUnxSPN9lXvP10bc36Jg2pa3A4jDL-FI3wu5sm1Arp4VSGGg~d09e1bf991c7af1ec76ad5ff91326c25

Analyst Recommendations on Affimed N.V.

Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	Apr. 01	MT
HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	Apr. 01	MT
Truist Securities Adjusts Price Target on Affimed to $6 From $8, Keeps Buy Rating	23-08-11	MT
Berenberg Assumes Affimed at Buy, Sets Price Target at $6	23-08-08	MT
HC Wainwright Trims Price Target on Affimed to $5 From $6, Maintains Buy Rating	23-06-05	MT
Berenberg Bank Adjusts Affimed Price Target to $6 From $10, Maintains Buy Rating	23-05-24	MT
Stifel Adjusts Price Target on Affimed to $1 From $2, Maintains Hold Rating	23-03-24	MT
Wells Fargo Adjusts Price Target on Affimed to $7 From $8, Maintains Overweight Rating	22-12-12	MT
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	22-12-12	MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	22-12-12	MT
SVB Securities Adjusts Affimed's Price Target to $6 From $10, Keeps Outperform Rating	22-12-12	MT
Piper Sandler Adjusts Affimed's Price Target to $6 From $7, Keeps Overweight Rating	22-12-12	MT
HC Wainwright Starts Affimed at Buy With $6 Price Target	22-12-12	MT
Stifel Downgrades Affimed to Hold From Buy, Adjusts Price Target to $2 From $9	22-10-10	MT
Berenberg Bank Adjusts Affimed's Price Target to $10 From $11, Maintains Buy Rating	22-08-12	MT
SVB Securities Adjusts Affimed Price Target to $9 From $10, Maintains Outperform Rating	22-06-23	MT
Affimed N.V.'s Potential Therapy for Lymphoma Shows 100% Objective Response Rate in Phase 1/2 Study	22-04-11	MT
Piper Sandler Starts Affimed at Overweight With $7 Price Target	22-03-31	MT
Cantor Fitzgerald Initiates Affimed at Overweight with $12 Price Target	22-02-23	MT
Affimed NV's Innate Cell Engager Achieves 100% Objective Response Rate In Phase 1/2 Lymphoma Study	21-11-22	MT
Berenberg Bank Initiates Coverage on Affimed With Buy Rating, $11 Price Target	21-11-17	MT
AFFIMED N : Truist Securities Initiates Affimed at Buy Rating With $10 Price Target	21-10-21	MT
AFFIMED N : SVB Leerink Adjusts Price Target on Affimed to $12 From $13, Maintains Outperform Rating	21-10-12	MT
AFFIMED N : Stifel Starts Affimed at Buy With $12 Price Target	21-09-30	MT
AFFIMED N : BMO Capital Adjusts Affimed's Price Target to $15 From $12, Keeps Outperform Rating	21-04-12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5 EUR

Average target price

20.83 EUR

Spread / Average Target

+316.60%

High Price Target

55.64 EUR

Spread / Highest target

+1,012.78%

Low Price Target

4.629 EUR

Spread / Lowest Target

-7.42%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Affimed N.V.

Wells Fargo Securities
HC Wainwright
Truist Securities
Berenberg Bank
Stifel Nicolaus
Piper Sandler
SVB Securities LLC
Cantor Fitzgerald
SVB Leerink
BMO Capital
Credit Suisse

Ratings for Affimed N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar